Insulet - PODD Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $310.91
Forecasted Upside: 8.10%
Number of Analysts: 12
Breakdown:
0 Sell Ratings
5 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$287.60 As of 02/7/2023 01:17 PM ET

▼ -4.57 (-1.56%)

1 month | 3 months | 12 months

Get New Insulet Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

^$310.91

▲ +8.10% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $310.91, with a high forecast of $345.00 and a low forecast of $245.00. The average price target represents a 8.10% upside from the last price of $287.60.

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Insulet. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

11/14/2021

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/12/2022

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/13/2022

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/11/2022

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

11/9/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/8/2023

0 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/7/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/26/2023	Wolfe Research	Initiated Coverage	Peer Perform		N/A
1/6/2023	Morgan Stanley	Boost Target	Equal Weight	$300.00 ➝ $320.00	Low
1/4/2023	Barclays	Boost Target		$238.00 ➝ $245.00	Low
12/12/2022	Robert W. Baird	Boost Target		$315.00 ➝ $340.00	Low
12/12/2022	Citigroup	Boost Target		$270.00 ➝ $330.00	Low
11/4/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$290.00 ➝ $310.00	Low
11/4/2022	BTIG Research	Boost Target		$285.00 ➝ $320.00	Low
11/4/2022	Citigroup	Boost Target		$260.00 ➝ $270.00	Low
11/4/2022	Morgan Stanley	Boost Target	Equal Weight	$273.00 ➝ $300.00	Low
11/4/2022	Piper Sandler	Upgrade	Neutral ➝ Overweight	$235.00 ➝ $340.00	Low
11/4/2022	Robert W. Baird	Boost Target	Outperform	$300.00 ➝ $315.00	Low
11/4/2022	Raymond James	Boost Target	Outperform	$280.00 ➝ $320.00	Low
10/17/2022	Barclays	Initiated Coverage	Equal Weight	$238.00	Low
10/12/2022	Jefferies Financial Group	Initiated Coverage	Hold	$260.00	Low
8/9/2022	Citigroup	Boost Target		$260.00	N/A
8/9/2022	BTIG Research	Boost Target		$285.00	N/A
8/8/2022	Morgan Stanley	Boost Target	Equal Weight	$244.00 ➝ $273.00	Low
8/8/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$250.00 ➝ $290.00	Low
8/5/2022	Canaccord Genuity Group	Boost Target	Buy	$250.00 ➝ $290.00	Low
8/5/2022	Robert W. Baird	Boost Target	Outperform	$245.00 ➝ $300.00	Low
8/5/2022	Raymond James	Boost Target		$262.00 ➝ $280.00	Low
8/5/2022	Piper Sandler	Boost Target	Neutral	$230.00 ➝ $235.00	Low
7/11/2022	Citigroup	Downgrade	Buy ➝ Neutral	$310.00 ➝ $250.00	N/A
6/24/2022	BTIG Research	Lower Target	Buy	$310.00 ➝ $250.00	Low
6/7/2022	Morgan Stanley	Lower Target	Equal Weight	$268.00 ➝ $244.00	Low
5/17/2022	Citigroup	Lower Target	Buy	$350.00 ➝ $310.00	N/A
5/6/2022	Wells Fargo & Company	Lower Target		$357.00 ➝ $345.00	High
3/2/2022	Bank of America	Initiated Coverage	Buy ➝ Buy		High
2/25/2022	Morgan Stanley	Lower Target	Equal Weight	$300.00 ➝ $268.00	High
2/24/2022	Raymond James	Lower Target	Outperform	$329.00 ➝ $280.00	High
2/24/2022	Robert W. Baird	Lower Target		$315.00 ➝ $275.00	High
2/24/2022	Piper Sandler	Lower Target	Neutral	$295.00 ➝ $230.00	High
2/3/2022	BTIG Research	Upgrade	Neutral ➝ Buy	$320.00	Medium
2/2/2022	UBS Group	Upgrade	Neutral ➝ Buy	$325.00	Low
1/31/2022	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$300.00 ➝ $275.00	High
1/7/2022	Morgan Stanley	Lower Target	Equal Weight	$303.00 ➝ $300.00	High
12/7/2021	SVB Leerink	Reiterated Rating	Buy		High
11/8/2021	Raymond James	Boost Target	Outperform	$285.00 ➝ $329.00	Medium
11/5/2021	Morgan Stanley	Boost Target	Equal Weight	$276.00 ➝ $303.00	High
11/5/2021	SVB Leerink	Boost Target	Outperform	$300.00 ➝ $350.00	High
11/5/2021	Citigroup	Boost Target	Buy	$325.00 ➝ $350.00	High
11/5/2021	Piper Sandler	Boost Target	Neutral	$262.00 ➝ $295.00	High
8/6/2021	SVB Leerink	Lower Target	Outperform	$325.00 ➝ $300.00	High
8/6/2021	Citigroup	Boost Target	Buy	$310.00 ➝ $325.00	High
7/21/2021	Cowen	Boost Target	Outperform	$285.00 ➝ $310.00	Low
7/20/2021	SVB Leerink	Boost Target	Outperform	$300.00 ➝ $325.00	Low
5/24/2021	Barclays	Initiated Coverage	Overweight	$300.00	Low
5/7/2021	Raymond James	Lower Target	Outperform	$296.00 ➝ $285.00	High
5/7/2021	SVB Leerink	Lower Target	Outperform	$320.00 ➝ $300.00	High
5/7/2021	Piper Sandler	Lower Target	Neutral	$260.00 ➝ $250.00	High
5/7/2021	BTIG Research	Reiterated Rating	Hold		High
4/1/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$275.00 ➝ $320.00	Low
3/2/2021	SVB Leerink	Boost Target	Market Perform	$255.00 ➝ $275.00	Low
2/25/2021	Oppenheimer	Boost Target	Market Perform	$235.00 ➝ $277.00	High
2/24/2021	SVB Leerink	Reiterated Rating	Market Perform	$255.00 ➝ $275.00	High
2/24/2021	Raymond James	Boost Target	Outperform	$282.00 ➝ $296.00	Low
2/1/2021	BTIG Research	Reiterated Rating	Hold		Low
1/29/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$260.00	Medium
1/15/2021	Wells Fargo & Company	Reiterated Rating	Buy		Medium
12/16/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$255.00 ➝ $268.00	Medium
12/15/2020	Morgan Stanley	Boost Target	Equal Weight	$246.00 ➝ $276.00	Low
11/5/2020	UBS Group	Boost Target	Neutral	$230.00 ➝ $245.00	Medium
11/5/2020	Wells Fargo & Company	Boost Target	Overweight	$250.00 ➝ $266.00	High
11/5/2020	Raymond James	Boost Target	Outperform	$249.00 ➝ $250.00	High
11/5/2020	Morgan Stanley	Boost Target	Equal Weight	$232.00 ➝ $246.00	High
10/12/2020	SVB Leerink	Boost Target	Market Perform	$240.00 ➝ $255.00	Low
8/7/2020	Morgan Stanley	Boost Target	Equal Weight	$222.00 ➝ $232.00	High
8/7/2020	Oppenheimer	Reiterated Rating	Hold	$235.00	Medium
8/7/2020	Stephens	Boost Target	Positive ➝ Equal Weight	$165.00 ➝ $230.00	Medium
8/7/2020	SVB Leerink	Boost Target	Market Perform	$215.00 ➝ $240.00	Medium
8/7/2020	Raymond James	Boost Target	Outperform	$200.00 ➝ $249.00	Medium
8/7/2020	Citigroup	Boost Target	Buy	$200.00 ➝ $255.00	Medium
8/6/2020	Piper Sandler	Reiterated Rating	Overweight	$235.00 ➝ $260.00	Medium
7/28/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$231.00	High
7/7/2020	Cowen	Boost Target	Positive ➝ Outperform	$220.00 ➝ $230.00	Low
6/9/2020	Raymond James	Lower Target	Outperform	$220.00 ➝ $200.00	Low
5/8/2020	Cfra	Boost Target	Sell	$162.00 ➝ $179.00	Low
5/8/2020	UBS Group	Boost Target	Neutral	$195.00 ➝ $213.00	High
5/8/2020	Stifel Nicolaus	Boost Target	Hold	$161.00 ➝ $195.00	High
5/8/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$200.00 ➝ $235.00	High
5/8/2020	Robert W. Baird	Boost Target		$189.00 ➝ $242.00	High
5/8/2020	Morgan Stanley	Boost Target	Equal Weight	$186.00 ➝ $222.00	Medium
5/8/2020	SVB Leerink	Boost Target	Market Perform	$200.00 ➝ $230.00	High
5/8/2020	Citigroup	Boost Target	Buy	$206.00 ➝ $250.00	High
4/27/2020	Raymond James	Boost Target	Outperform	$205.00 ➝ $220.00	Medium
4/24/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
4/3/2020	Bank of America	Initiated Coverage	Neutral	$200.00	Medium
3/31/2020	Berenberg Bank	Downgrade	Buy ➝ Hold		High
3/27/2020	Morgan Stanley	Boost Target	Equal Weight	$181.00 ➝ $186.00	Low
3/27/2020	Citigroup	Lower Target	Buy	$220.00 ➝ $206.00	Medium
3/4/2020	Citigroup	Initiated Coverage	Buy	$220.00	Low
2/26/2020	Piper Sandler	Reiterated Rating	Buy	$200.00	High
2/26/2020	Cowen	Reiterated Rating	Buy		High
2/26/2020	Cfra	Lower Target	Sell	$163.00 ➝ $162.00	Low
2/26/2020	Robert W. Baird	Lower Target	Outperform	$225.00 ➝ $215.00	High
2/26/2020	BTIG Research	Reiterated Rating	Hold		High
2/26/2020	Raymond James	Lower Target	Outperform	$213.00 ➝ $205.00	High
2/6/2020	Raymond James	Boost Target	Outperform	$158.00 ➝ $213.00	Medium
12/20/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$170.00 ➝ $200.00	Medium
12/17/2019	Morgan Stanley	Boost Target	Equal Weight	$148.00 ➝ $181.00	Low
12/10/2019	Cfra	Initiated Coverage	Sell	$163.00	Medium
11/18/2019	Piper Jaffray Companies	Boost Target	Overweight	$170.00 ➝ $200.00	Low
11/6/2019	Raymond James	Boost Target	Outperform	$135.00 ➝ $158.00	High
11/6/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$160.00 ➝ $170.00	High
10/22/2019	Stifel Nicolaus	Initiated Coverage	Hold	$163.00	High
10/21/2019	Cowen	Set Target	Buy	$165.00	Medium
10/14/2019	BTIG Research	Downgrade	Buy ➝ Neutral		Medium
10/4/2019	UBS Group	Downgrade	Buy ➝ Neutral	$155.00 ➝ $160.00	Low
10/3/2019	Guggenheim	Downgrade	Buy ➝ Neutral		Medium
9/24/2019	SVB Leerink	Boost Target	Outperform	$160.00 ➝ $185.00	High
9/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy		Low
8/6/2019	Morgan Stanley	Boost Target	Equal Weight	$127.00 ➝ $135.00	High
8/6/2019	BTIG Research	Boost Target	Buy	$140.00	High
8/6/2019	BMO Capital Markets	Boost Target	Outperform	$130.00 ➝ $150.00	High
8/6/2019	Jefferies Financial Group	Boost Target	Buy	$105.00 ➝ $140.00	High
8/6/2019	Raymond James	Boost Target	Outperform	$125.00 ➝ $135.00	High
8/6/2019	Guggenheim	Boost Target	Buy ➝ Positive	$100.00 ➝ $145.00	High
8/6/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$120.00 ➝ $155.00	High
8/6/2019	Piper Jaffray Companies	Boost Target	Overweight	$130.00 ➝ $160.00	High
7/16/2019	Morgan Stanley	Boost Target	Equal Weight	$98.00 ➝ $127.00	Low
7/10/2019	SVB Leerink	Reiterated Rating	Outperform		Low
6/28/2019	Piper Jaffray Companies	Boost Target	Overweight ➝ Positive	$110.00 ➝ $130.00	High
6/27/2019	JPMorgan Chase & Co.	Boost Target	Neutral	$90.00 ➝ $120.00	Low
6/13/2019	UBS Group	Boost Target	Buy	$110.00 ➝ $130.00	Low
6/10/2019	Northland Securities	Downgrade	Outperform ➝ Market Perform	$100.00	Low
5/6/2019	BTIG Research	Upgrade	Neutral ➝ Buy	$115.00	High
2/26/2019	Oppenheimer	Set Target	Hold	$100.00	Medium
2/26/2019	Northland Securities	Reiterated Rating	Buy	$100.00	High
1/3/2019	SVB Leerink	Reiterated Rating	Outperform	$110.00 ➝ $100.00	Medium
1/2/2019	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$105.00 ➝ $90.00	High
11/27/2018	UBS Group	Initiated Coverage	Buy	$105.00	Medium
11/2/2018	Oppenheimer	Set Target	Hold	$100.00	High
10/11/2018	Morgan Stanley	Boost Target	Equal Weight	$96.00 ➝ $105.00	Medium
9/11/2018	SVB Leerink	Reiterated Rating	Outperform	$130.00	Medium
8/3/2018	Jefferies Financial Group	Reiterated Rating	Buy	$97.00	Low
8/3/2018	Oppenheimer	Set Target	Hold	$96.00	High
7/10/2018	BMO Capital Markets	Boost Target	Top Pick	$115.00	Medium
6/4/2018	Piper Jaffray Companies	Boost Target	Overweight	$106.00	Low
6/1/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$87.00 ➝ $96.00	Low
5/4/2018	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$90.00 ➝ $100.00	High
5/4/2018	Northland Securities	Reiterated Rating	Buy	$100.00	Low
5/4/2018	Oppenheimer	Set Target	Hold	$90.00	High
5/3/2018	Piper Jaffray Companies	Boost Target	Overweight	$88.00 ➝ $90.00	High
4/20/2018	Berenberg Bank	Initiated Coverage	Buy	$100.00	Medium
4/3/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Low
3/5/2018	BMO Capital Markets	Initiated Coverage	Outperform	$90.00	High
2/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	Low
2/22/2018	Cowen	Reiterated Rating	Outperform ➝ Outperform	$80.00 ➝ $90.00	Medium
2/22/2018	Oppenheimer	Set Target	Hold	$82.00	High
2/22/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$76.00 ➝ $87.00	High
2/22/2018	Stephens	Reiterated Rating	Equal Weight ➝ Equal Weight	$60.00 ➝ $81.00	High
2/22/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$85.00 ➝ $90.00	High

(Data available from 2/7/2018 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/12/2022

2 very positive mentions
14 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/11/2022

5 very positive mentions
15 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

9/10/2022

4 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/10/2022

6 very positive mentions
13 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/9/2022

5 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/9/2022

5 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/8/2023

15 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/7/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Today's Range

Now: $287.60

$283.01

$290.97

50 Day Range

MA: $296.24

$279.72

$313.00

52 Week Range

Now: $287.60

$181.00

$320.00

Volume

35,941 shs

Average Volume

365,530 shs

Market Capitalization

$19.97 billion

P/E Ratio

1,198.33

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?: The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Bank of America Co., Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for PODD.
What is the current price target for Insulet?: 11 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $310.91, suggesting a possible upside of 6.4%. Wells Fargo & Company has the highest price target set, predicting PODD will reach $345.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $245.00 for Insulet in the next year.
View the latest price targets for PODD.
What is the current consensus analyst rating for Insulet?: Insulet currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PODD will outperform the market and that investors should add to their positions of Insulet.
View the latest ratings for PODD.
What other companies compete with Insulet?: Other companies that are similar to Insulet include Abiomed, Baxter International, Teleflex, Globus Medical and ResMed. Learn More about companies similar to Insulet.
How do I contact Insulet's investor relations team?: Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is (978) 600-7000 and its investor relations email address is [email protected] The official website for Insulet is www.insulet.com. Learn More about contacing Insulet investor relations.

Insulet - PODD Stock Price Target and Predictions

Analyst Price Target for PODD

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.03 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

What is the current price target for Insulet?

What is the current consensus analyst rating for Insulet?

What other companies compete with Insulet?

How do I contact Insulet's investor relations team?